Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Carboplatin 9pembrolizumab 8Paclitaxel 8Cisplatin 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Gemcitabine 5fludarabine 4Specimen Handling 4Pemetrexed 4Nivolumab 4Cyclophosphamide 4trebananib 3osimertinib 3liposomal doxorubicin 3Radiotherapy 3Interleukin-2 3Fluorouracil 3Docetaxel 3DNA 3volociximab 2poly ICLC 2lenvatinib 2fludarabine phosphate 2Sorafenib 2Radiosurgery 2Midazolam 2Capecitabine 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma × Meperidine × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡